Cue Biopharma (CUE) Gains from Investment Securities (2017 - 2025)

Cue Biopharma has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $2.7 million for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $2.7 million, up 93.16% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (up 93.16% YoY), and the FY2025 annual result was $2.7 million, up 93.16% from the prior year.
• Gains from Investment Securities came in at $2.7 million for Q4 2025 at Cue Biopharma, down from $13.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.8 million in Q3 2025 to a low of $35000.0 in Q3 2021.
• The 5-year median for Gains from Investment Securities is $1.6 million (2022), against an average of $3.4 million.
• Peak annual rise in Gains from Investment Securities reached 10108.33% in 2021, while the deepest fall reached 85.11% in 2021.
• Cue Biopharma's Gains from Investment Securities stood at $35000.0 in 2021, then surged by 4688.57% to $1.7 million in 2022, then soared by 53.75% to $2.6 million in 2023, then sank by 45.5% to $1.4 million in 2024, then surged by 93.16% to $2.7 million in 2025.
• The last three Gains from Investment Securities figures came in at $2.7 million (Q4 2025), $13.8 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.